User asks about topical spironolactone experience. Two studies show it as promising anti-androgen treatment, with 5% cream available on Minoxidilmax website.
The conversation is about seeking advice on the potential benefits of two different hair sprays for hair loss, with a list of ingredients provided for each. Specific treatments were not discussed.
Verteporfin is being explored for hair regeneration, with unofficial trials and updates shared online. Efforts are being made to encourage more surgeons to trial verteporfin for donor hair regeneration.
Zeuss sublingual products for hair loss, including finasteride and a finasteride-free option, are discussed for their potential to reduce side effects through sublingual delivery. The inclusion of copper peptides is noted, but the high price is a concern without more user feedback.
Nicotinamide serum is discussed for its potential benefits in reducing inflammation related to hair loss. One user combines it with minoxidil for hair growth.
The conversation discusses using ZIX, a combination of Zinc Sulfate and Vitamin B6, for hair loss. The user is considering liquid forms for better absorption and scalp health.
A dermatologist recommended a new supplement containing annurca apple, which reportedly doubles hair density and increases keratin after 60 days, to be used with finasteride. Some users are skeptical, considering it potentially ineffective or a marketing ploy, while others are open to trying it if it proves effective and affordable.
The conversation is about the effectiveness of a hair loss treatment product containing 0.01% Latanoprost, with the user considering trying it as a vehicle for RU58841. The user questions whether the dosage is too low to be effective.
The conversation discusses the use of Procapil 5% for hair loss. Users inquire about its effectiveness and share experiences with treatments like Minoxidil, Finasteride, and RU58841.
Treating hair loss with finasteride, dutasteride and minoxidil, as well as micro-needling, potentially using research chemicals such as Pyril and Senzu Beans.
A hair restoration case involved injecting four different doses of Verteporfin into the mid scalp and using Scalp MicroPigmentation (SMP) around the extraction areas. Photos were taken and an update will be shared soon.
Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.
The conversation discusses RU58841, a compound for hair loss treatment, which was found to be effective in a 6-month trial but was not pursued due to financial issues or marketability concerns, not safety. Some users are considering crowdfunding to release the research data, while others discuss personal experiences and safety concerns with RU58841.
2-deoxy-d-ribose hair serum is now available in Australia, potentially aiding hair loss by promoting new blood vessel growth. Users are discussing its potential effectiveness compared to other treatments like Minoxidil, finasteride, and RU58841.
A treatment showed a 20% hair density increase in weeks, with nearly a third of participants experiencing significant results, while questions remain about its long-term efficacy and effectiveness across different scalp areas. There is interest in combining it with finasteride and minoxidil for potentially better outcomes.
Topical spironolactone is more effective than topical finasteride for treating hair loss in both men and women. Oral spironolactone can affect testosterone, but the topical form doesn't impact the endocrine system.
A user is asking where to find Tretinoin/retinol serum in the UK to use alongside Minoxidil for better hair growth results. They believe Tretinoin can enhance Minoxidil's effectiveness.
A user from China is participating in a clinical trial for Pyrilutamid, a potential hair loss treatment originally developed for prostate cancer. They've experienced no side effects except initial scalp itchiness, and will share results after the year-long trial.
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.
Setipiprant trial for hair loss failed, showing no difference between placebo and treatment. Discussion also noted placebo users reporting side effects.
A user noticing changes in the L'Oreal Serioxyl hair treatment, including a different smell, mismatched batch numbers, and a color change. They question if it's a new formula and seek alternatives to stemoxydine. Another user questions if the positive results were due to stemoxydine or other medications.
PP405 is discussed as a potential adjunct therapy for hair loss, with skepticism about its effectiveness and trial results. Users mention combining it with finasteride and minoxidil for better results, while others debate the root causes of hair loss and the limitations of current treatments.
Emerging hair loss treatments like PP405, a topical MPC inhibitor, show promise in activating stem cells for hair growth. The conversation seeks information on the development stages and accessibility of these treatments.
Minoxidil and finasteride are being considered for hair loss due to seborrheic dermatitis and male pattern baldness. The user is also using ketoconazole and zinc pyrithione shampoo.